Is Sorrento Therapeutics a Top Stock to Buy Now?
Year to date, shares of Sorrento Therapeutics (NASDAQ: SRNE) have been crushing their peers in the biotech sector, largely thanks to the expansion of the company's coronavirus testing and treatment pipeline. In the span of six months, the company's stock has returned more than 327%, whereas the iShares Nasdaq Biotech ETF (NASDAQ: IBB) is up just less than 11%. An investment of $10,000 at the beginning of the year would have been worth $42,750 as of market close on Aug. 11. Given its current rate of compounding, investors may be wondering if Sorrento is one of the top growth stocks to buy now.
While the company has had its fair share of controversy, it also has a robust pipeline that can enrich investors. Just how much faith should investors put toward its science?
Image source: Getty Images.
Source Fool.com
